Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,566Revenue $M131Net Margin (%)-36.2Altman Z-Score9.2
Enterprise Value $M4,422EPS $-0.5Operating Margin %-105.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score38.6Pre-tax Margin (%)-38.2Higher ROA y-yY
Price/Book9.610-y EBITDA Growth Rate %--Quick Ratio2.7Cash flow > EarningsY
Price/Sales33.05-y EBITDA Growth Rate %--Current Ratio2.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-7.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-10.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M110ROIC % (ttm)-45.0Gross Margin Increase y-yN

Gurus Latest Trades with XON

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XONFirst Eagle Investment 2015-06-30 Add0.01%$37.33 - $50.71
($42.54)
$ 41.60-2%Add 5.37%872,604
XONFirst Eagle Investment 2015-03-31 Add$26.08 - $50.16
($37.59)
$ 41.6011%Add 4.84%828,104
XONT Boone Pickens 2014-12-31 Buy 0.53%$16.61 - $28.02
($23.05)
$ 41.6080%New holding10,000
XONDavid Einhorn 2014-12-31 Sold Out -0.05%$16.61 - $28.02
($22.97)
$ 41.6081%Sold Out0
XONDavid Einhorn 2014-09-30 Reduce-0.06%$17.86 - $26.59
($21.29)
$ 41.6095%Reduce 47.39%197,278
XONDavid Einhorn 2014-06-30 Reduce-0.39%$15.3 - $25.93
($21.15)
$ 41.6097%Reduce 72.81%375,000
XONFirst Eagle Investment 2014-06-30 Buy 0.04%$15.3 - $25.93
($21.15)
$ 41.6097%New holding661,564
XONDavid Einhorn 2014-03-31 Reduce-0.26%$22.5 - $36.82
($28.82)
$ 41.6044%Reduce 37.58%1,379,014
XONT Boone Pickens 2013-12-31 Sold Out -0.47%$17.65 - $25.5
($21.05)
$ 41.6098%Sold Out0
XONDavid Einhorn 2013-09-30 Buy 0.86%$21.36 - $29.7
($24.16)
$ 41.6072%New holding2,176,868
XONT Boone Pickens 2013-09-30 Buy 0.47%$21.36 - $29.7
($24.16)
$ 41.6072%New holding12,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XON is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2015-01-27Buy555,556$2760.04view
KIRK RANDAL JCEO, 10% Owner 2014-05-13Buy65,173$15.19184.46view
Lehr Donald P.Chief Legal Officer 2014-05-13Buy1,850$15.99170.23view
Reed Thomas D.Chief Science Officer 2014-05-13Buy640$15.6176.99view
Krishnan SumaSVP--Product Development 2014-05-09Buy20,900$14.21204.08view
Krishnan Krish SCOO 2014-05-09Buy20,900$14.21204.08view
Kasser Thomas R.SVP--Food Sector 2014-05-09Buy10,000$13.39222.7view
Huang KellySVP-Consumer Sector 2014-05-09Buy3,200$15.78173.83view
KIRK RANDAL JCEO, 10% Owner 2014-05-09Buy67,333$15.16185.03view
KIRK RANDAL JCEO, 10% Owner 2014-03-27Buy243,001$25.7268view

Quarterly/Annual Reports about XON:

    News about XON:

    Articles On GuruFocus.com
    Intrexon Corp is expanding his business Jun 25 2015 
    Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
    5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
    Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
    Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
    David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
    Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

    More From Other Websites
    2 Catalysts Driving Intrexon to All-Time Highs Sep 01 2015
    ZIOPHARM Announces Cancer Research Publication of Study Demonstrating Preferential Targeting of... Sep 01 2015
    Jim Cramer's Top Takeaways: Ulta Salon, Cheniere Energy, Intrexon Sep 01 2015
    Cramer: The Street fight over Intrexon Aug 31 2015
    Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for... Aug 31 2015
    Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS Aug 27 2015
    Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS Aug 27 2015
    Intrexon Corp. Earnings Q2, 2015 Aug 26 2015
    Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise... Aug 26 2015
    Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise... Aug 26 2015
    INTREXON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Aug 21 2015
    Intrexon Prices Public Offering of Common Stock Aug 21 2015
    Intrexon Prices Public Offering of Common Stock Aug 21 2015
    Intrexon Announces Proposed Public Offering of Common Stock Aug 20 2015
    Intrexon Announces Proposed Public Offering of Common Stock Aug 20 2015
    INTREXON CORP Financials Aug 20 2015
    Intrexon Energy Partners and Dominion Enter Exclusive Agreement in Marcellus and Utica Basins to... Aug 20 2015
    Intrexon Energy Partners and Dominion Enter Exclusive Agreement in Marcellus and Utica Basins to... Aug 20 2015
    Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine Aug 19 2015
    Lightning Round: Hottest biotech I've ever seen Aug 17 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK